Fair Value Measurements - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares	436,418,964		436,418,964		314,573,225
Common stock shares value subject to transfer restrictions	$ 63,259		$ 63,259		$ 90,217
Gain (Loss) on derivative liability	$ (2,700)	$ (300)	4,800	$ 1,900
Senior Notes | Scilex Pharmaceuticals, Inc
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Decrease in fair value of derivative liability			$ 30,400
Class A Common Stock | Celularity
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, shares outstanding (in shares) | shares	20,422,124		20,422,124
Common stock received | shares			19,922,124
Common stock shares value subject to transfer restrictions	$ 61,600		$ 61,600
Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	21.5		21.5
Risk Adjusted Net Sales Forecast
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	0.061		0.061
Discount for Lack of Marketability
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Discount rate for lack of marketability	0.09		0.09
ACEA Therapeutics, Inc
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Gain on re-measurement of fair value	$ 64,300		$ 66,400
ACEA Therapeutics, Inc | Effective Debt Yield
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Derivative liability, measurement input	21.5		21.5